Comparative Evaluation of Nimesulide-Loaded Nanoparticles for Anticancer Activity Against Breast Cancer Cells
详细信息 查看全文
- 作者：Ceyda Tuba Sengel-Turk ; Canan Hascicek ; Filiz Bakar ; Elif Simsek
- 关键词：apoptosis ; MCF ; 7 cells ; nimesulide ; PEG ; block ; PCL ; polymeric nanoparticles
- 刊名：AAPS PharmSciTech
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：18
- 期：2
- 页码：393-403
- 全文大小：
- 刊物主题：Pharmacology/Toxicology; Biotechnology; Biochemistry, general; Pharmacy;
- 出版者：Springer US
- ISSN：1530-9932
- 卷排序：18
文摘
Recent clinical and epidemiological researches have declared that non-steroidal anti-inflammatory agents may display as antineoplastic agents and indicate pro-apoptotic and antiproliferative effects on cancer cells. The major purpose of this research was to develop a novel poly(ethyleneglycol)-block-poly(ε-caprolactone) (PEG-b-PCL) nano-sized particles encapsulated with nimesulide (NMS), a selective COX-2 inhibitor, and to evaluate its anticancer activity against MCF-7 breast cancer cells. NMS-encapsulated PEG-b-PCL nanoparticles were fabricated using three different production techniques: (i) by emulsion-solvent evaporation using a high shear homogenizer, (ii) by emulsion-solvent evaporation using an ultrasonicator, and (iii) by nanoprecipitation. Nanoparticles were evaluated with respect to the entrapment efficiency, size characteristics, drug release rates, thermal behavior, cell viability assays, and apoptosis. The resulting nanoparticles were found to be spherical shapes with negative surface charges. The average diameter of all nanoparticles ranged between 148.5 and 307.2 nm. In vitro release profiles showed that all nanoparticles exhibited a biphasic release pattern. NMS-loaded PEG-b-PCL nanoparticles demonstrated significant anticancer activity against MCF-7 breast cancer cells in a dose-dependent manner, and the effects of nanoparticles on cell proliferation were significantly affected by the preparation techniques. The nanoparticles developed in this work displayed higher potential for the NMS delivery against breast cancer treatment for the future.